News

Stuart W. Titus, PhD, President and CEO of Medical Marijuana Inc. mentions: "We are extremely excited to announce our strategic ownership interest in AXIM Biotech and explain to

With the close of this acquisition, management believes that the Company will be able to offer comprehensive immuno-oncology cell therapy portfolios, as well as a broad set of

The Phase 1 study will evaluate the safety and immune response profile of the DPX-RSV vaccine candidate in healthy adults. The study, conducted at the Canadian Center for

The acquisition will expand AMAG’s suite of maternal health business and add improved commercial capabilities as well as future growth opportunities to its portfolio. CBR’s storage facility houses

Dr. Daniel Teper, CEO of Immune, commented: "We believe that the new formulation of AmiKet may increase value to potential commercial partners and to Immune. As a result

Vibativ is a bactericidal, once-daily antibiotic with in vitro potency and a dual mechanism of action against Gram-positive bacteria. Russian pharmaceutical firm R-Pharm will be responsible to market

The company said that the EORA program was awarded a Blueprint Neurotherapeutics (BPN) grant from the National Institutes of Health (NIH) to develop the program from the preclinical

The company has completed enrollment and dosing in a Phase I clinical trial of Aerucin and the results are expected to be reported in the fourth quarter of

LIPO-202 is an injectable formulation of salmeterol xinafoate, a long-acting ß2-adrenergic receptor agonist used in several FDA-approved drugs, including Advair, which is indicated to treat asthma. In the